Private company

Laboratoires Servier

Logo: Unknown author Unknown author, Public domain, via Wikimedia Commons⁴

International pharmaceutical company governed by a non-profit foundation

Servier Laboratories (French: Laboratoires Servier, often abbreviated to Servier) is an international pharmaceutical company founded by Jacques Servier and now governed by a non-profit foundation, with its headquarters in France (Suresnes). The consolidated turnover for the 2018 financial year was €4.2 billion. Servier is the leading French independent pharmaceutical company, and the second largest French pharmaceutical company.² Its chief executive is Olivier Laureau (since 2014).¹ It employed about 21,000 people.¹ Wikipedia text CC BY-SA 4.0

Last updated Oct 21, 2026.

Overview

1954Founded¹

HeadquartersSuresnes, France¹
Websiteservier.com
Legal formsociété par actions simplifiée¹
LEI969500Y8PG1HQ9Y6NA31³
StatusActive³
LEI statusIssued and current³
Registered address50 RUE CARNOT, 92150 Suresnes, France³
Registered withNational Institute of Statistics and Economic Studies, 085480796³

See how the biggest companies compare on our leaderboards

Corporate structure

Laboratoires Servier sits at the top of its group. 3 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Laboratoires Servier Suresnes, France
- BIOGARAN Subsidiary · Colombes, France
- Servier (United Kingdom) Subsidiary · United Kingdom

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries, stakes and holdings from Wikidata (CC0). Each entity in the chart links to its source.

Leadership

Who has led Laboratoires Servier, and when. Pick a name to see everywhere that person has worked.

Chief executive

197019801990200020102020

FounderJacques Servier¹
Chief executive officerOlivier Laureau Apr 2014 to now¹
Chief executive officerJacques Servier 1954 to Apr 2014¹

Products and brands

medication

Listed on Wikidata.¹

Product portfolio

Notable products:

Gliclazide (Diamicron, Diamicron MR) — antidiabetic drug

Indapamide (Fludex SR, Natrilex SR, Lozide) — diuretic

Ivabradine (Procoralan)

Read the full text

Perindopril (Coversyl) — ACE inhibitor

Strontium ranelate (Protelos) — osteoporosis agent

Amineptine (Survector, Maneon, Directim)

Tianeptine (Stablon)

Trimetazidine (Vastarel MR) — antianginal drug.

Other products:

Agomelatine (Valdoxan, Melitor, Thymanax)

Almitrine (Duxil, Vectarion)

Benfluorex (Mediaxal)

Carbutamide (Glucidoral)

Daflon 500

Fenspiride (Pneumorel)

Fotemustine (Muphoran)

Fusafungine (Locabiotal)

Gliclazide (Diamicron)

Indapamide (Natrilix, Tertensif, Lozide)

Pegaspargase (Oncaspar) — Acute lymphoblastic leukemia treatment

Perindopril (Coversyl, Prestarium)

Perindopril/indapamide (Preterax, Coversyl Plus)

Piribedil (Trivastal retard)

Rilmenidine (Hyperium)

Tianeptine (Coaxil, Stablon)

Sodium alginate (Pseudophage)

Sulbutiamine (Arcalion)

Tertatolol (Artex)

Vitamins (Vitathion)

Collaborative research

As well as internal research and development activities, Servier undertakes publicly funded collaborative research projects with industrial and academic partners. One example, in the area of non-clinical safety assessment, is the InnoMed PredTox. The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.

In addition to these, Servier engages in research and licensing collaborations across the pharmaceutical and biotechnology industry. These collaborations include:

In Cardiology: XENTION (UK, 2013), AMGEN (USA, 2013), MIRAGEN (USA, 2011), ARMGO (USA, 2006)

In Diabetes: INTARCIA (USA, 2014)

In Metabolic diseases: INTERCEPT - TGR5 agonists (USA, 2011), Genfit (FR, 2004)

In Neurology (MS): GENEURO (CH, 2014)

In Oncology: CTI BIOPHARMA (USA, 2014), NOVARTIS (CH, 2014), CELLECTIS (FR, 2014), NERVIANO (IT, 2013), EOS (IT) / CLOVIS (USA, 2012), BIOINVENT (SE, 2012), MACROGENICS (USA, 2011/12), GALAPAGOS (NDL, 2011), BIOREALITES (FR, 2011), PHARMACYCLICS - HDAC inhibitor (USA, 2009), HYBRIGENICS (FR, 2007/2011) VERNALIS (UK, 2007/2011)

In Orphan Diseases/Cardiology/Diabetes: XOMA (USA, 2010)

In Osteoporosis & Osteoarthritis: OSTEOLOGIX (USA, 2010), GALAPAGOS (NDL, 2010), KAROS (USA, 2010), NORDIC BIOSCIENCE (DK, 2006/2010)

Servier acquired Symphogen in 2020.

From Wikipedia’s article on Laboratoires Servier, shared under CC BY-SA 4.0.⁵

Subsidiaries and ownership

Subsidiaries

Servier (United Kingdom)

From Wikidata.¹

Revenue over time

As stated on Wikidata, in the currency reported.

Revenue

2022160.8M EUR¹

Net income

2022-46.0M EUR¹

Controversies and legal

Controversy

Servier Laboratories has been the subject of worldwide scandal for creating and distributing a weight-loss drug called Mediator (Benfluorex), which may have killed up to 2,100 people.

The movie 150 Milligrams, by director Emmanuelle Bercot, features Dr. Irène Frachon discovering that Mediator pills cause heart valve problems/deaths and how in 2009 she starts an uphill battle against the producer and the French health authorities.

In March 2021, Servier was sentenced to a fine of 2.7 million euros for aggravated deception and involuntary manslaughter, however it was acquitted of fraud charges. The court also ordered the company to pay several hundred million euros in damages to the 6,500 plaintiffs, and one of its leading managers was sentenced to four years on probation. The French medical agency ANSM was fined 300,000 euros for failing proper supervision.

A French pharmaceutical company, continued its operations in Russia despite international sanctions and the geopolitical consequences of Russia's invasion of Ukraine. The company's decision to maintain its presence in the region was criticized by organizations advocating for ethical corporate conduct during global conflicts.